A multicenter , active-controlled , open-label , randomized trial is to be performed to evaluate dual antithrombotic therapy ( ticagrelor + warfarin ) in persistent or permanent AF patients ( score of CHADSVASc2 ) after PCI-eS versus the combination of triple antithrombosis ( clopidogrel + aspirin + warfarin ) .